Brunet, Joan

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

EMBRACE, Kuchenbaecker, K. B., Collaborators, G. S., Breast Cancer Family Registry, HEBON, KConFab Investigators, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, the Consortium of Investigators of Modifiers of BRCA1 and BRCA2, Ramus, S. J., et al. (2015) · Nature Genetics

BRCA gene mutations in cancerOvarian cancer diagnosis and treatment

Cited by 250

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyEstrogen and related hormone effects

Cited by 161

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

Cuyàs, E., Verdura, S., Llorach-Parés, L., Fernández-Arroyo, S., Joven, J., Martin-Castillo, B., Bosch-Barrera, J., Brunet, J., Nonell-Canals, A., Sanchez-Martinez, M., et al. (2018) · Frontiers in Endocrinology

Sirtuins and Resveratrol in MedicineComputational Drug Discovery Methods

Cited by 122

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild‐type tumor cells

Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., Queralt, B., Báez, L., Guardeño, R., Hernández‐Yagüe, X., Martin‐Castillo, B., Brunet, J., & Menendez, J. A. (2011) · Journal of Cellular Biochemistry

Colorectal Cancer Treatments and StudiesCancer Cells and Metastasis

Cited by 47

ATM germline mutations in Spanish early‐onset breast cancer patients negative for BRCA1/BRCA2 mutations

Brunet, J., Gutiérrez‐Enríquez, S., Torres, A., Bérez, V, Sanjosé, S., Galceran, J., Izquierdo, À., Menéndez, J., Gumà, J., & Borràs, J. (2008) · Clinical Genetics

BRCA gene mutations in cancerGenetic factors in colorectal cancer

Cited by 21

A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).

Bhulani, N., Wood, M., Tsai, J., Bedrosian, I., Hopkins, J. O., Brunet, J., Michaelson-Cohen, R., Schmutzler, R. K., Evans, G. D., Gnant, M., et al. (2022) · Journal of Clinical Oncology

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 10